Clinical Trial Update: Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the safety and pharmacokinetics of escalating doses of DNIB0600A in participants with non-small cell lung cancer and platinum-re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• DNIB0600A

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED